Allergan (AGN) reports its business revenues in three business segments: US Specialized Therapeutics, US General medicines, and International. For 3Q17, Allergan reported an 11.4% YoY (year-over-year) rise in revenues to $4.03 billion, compared with its revenues of $3.62 billion in 3Q16.
For 3Q17, AGN’s growth was driven by the strong performance of its specialized therapeutic products in the US and outside of the US as well as by the strong performance of its central nervous system and gastrointestinal products. These gains were offset by lower sales from women’s health and anti-infective products and diversified brands in General Medicines.
Revenues in 3Q17
Allergan met the Wall Street analysts’ estimates for revenues, reporting $4.03 billion in 3Q17, which was 11.4% higher YoY, compared with $3.62 billion in 3Q16. Allergan surpassed the estimates for EPS (earnings per share) at $4.15, compared with the estimate of $4.05.
This growth in revenues was driven by the strong performance of eye care, medical aesthetics, and neuroscience and urology products from the US specialized therapeutics product portfolio. Growth was also driven by central nervous system, gastrointestinal, and anti-infective products in the US, as well as from eye care, medical aesthetics, and botox therapeutics products in international markets.
AGN’s growth was also driven by the inclusion of LifeCell’s product portfolio, partially offset by the divestiture of its generics business and its ANDA distribution business to Teva Pharmaceuticals (TEVA) during 2016.
Notably, the VanEck Vectors Biotech ETF (BBH) has 5.1% of its total investments in Allergan (AGN). BBH also has 4.6% in BioMarin Pharmaceutical (BMRN), 5.8% in Biogen (BIIB), and 7.7% in Celgene (CELG).